NBY - NovaBay Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
1.1000
+0.1200 (+12.24%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.9800
Open0.9997
Bid0.7000 x 900
Ask1.3000 x 2200
Day's Range0.9997 - 1.1000
52 Week Range0.7100 - 3.7500
Volume7,815
Avg. Volume31,677
Market Cap18.963M
Beta (3Y Monthly)3.86
PE Ratio (TTM)N/A
EPS (TTM)-0.4610
Earnings DateMar 19, 2019 - Mar 22, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • Business Wire3 days ago

    NovaBay Pharmaceuticals Announces Annual Meeting of Stockholders and Receives NYSE American Communication

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will hold a virtual Annual Meeting of Stockholders on Thursday, May 30, 2019 at 5:00 p.m. Pacific time. Registered holders and beneficial stockholders, who register for the meeting in advance, will be able to participate in the meeting, vote and submit questions during the meeting via a live webcast by visiting www.meetingcenter.io/263757134. The Company also notes that on April 12, 2019 it received notice (the “Notice”) from the NYSE American LLC that it is not in compliance with Section 1003(a)(iii) of the NYSE American Company Guide requiring stockholders’ equity of $6.0 million or more if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years.

  • Business Wire5 days ago

    NovaBay Pharmaceuticals Announces New Partner Pharmacy Program

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company, announces a new pharmacy partnering program in a continued effort to ensure all patients in the U.S. have reliable and affordable access to prescription Avenova®. The company’s pharmacy partners serve patients across the U.S., and together ensure patients in all 50 states have convenient access to Avenova. “Our commitment to a quality patient experience, along with our expanding national presence ensures every patient who wants Avenova can obtain it at the best price,” said Dan Richards, CEO of Meds In Motion Pharmacy, one of Avenova’s channel partners.

  • Business Wire22 days ago

    NovaBay Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results

    Conference call begins today at 4:30 p.m. Eastern time

  • ACCESSWIRE23 days ago

    NovaBay Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 28, 2019 / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 28, ...

  • Business Wirelast month

    NovaBay Pharmaceuticals Announces Strategic Shift in U.S. Avenova Commercialization Strategy

    Makes board and executive changes and reduces U.S. sales organization to focus only on high-performing, high potential sales territories and specialty pharmacy channel expansion

  • Analysts Estimate NovaBay Pharmaceuticals (NBY) to Report a Decline in Earnings: What to Look Out for
    Zackslast month

    Analysts Estimate NovaBay Pharmaceuticals (NBY) to Report a Decline in Earnings: What to Look Out for

    NovaBay (NBY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire3 months ago

    NovaBay Pharmaceuticals Announces Preliminary 2018 Net Sales and Introduces 2019 Net Sales Guidance

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces 2018 net sales are expected to be $12.6 million to $12.7 million. “During 2018 we launched a number of refinements to our Avenova commercial strategy as we gained experience from our initial approach,” said Jack McGovern, NovaBay Interim CEO and CFO. “Key drivers of our expected growth include engaging specialty pharmacy providers as channel partners, which provides the dual benefit of significantly improving the overall patient experience and supporting higher per-unit revenue,” he added.

  • Business Wire5 months ago

    NovaBay Pharmaceuticals Reports Third Quarter 2018 Financial Results

    Conference call begins today at 4:30 p.m. Eastern time

  • Business Wire5 months ago

    NovaBay Pharmaceuticals to Hold Third Quarter 2018 Conference Call on November 14, 2018

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will report third quarter 2018 financial results after market close on Wednesday, November 14.

  • Will NovaBay Pharmaceuticals (NBY) Report Negative Earnings Next Week? What You Should Know
    Zacks5 months ago

    Will NovaBay Pharmaceuticals (NBY) Report Negative Earnings Next Week? What You Should Know

    NovaBay (NBY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire7 months ago

    NovaBay Pharmaceuticals Names Jack McGovern Interim CEO

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that Jack McGovern has been named Interim Chief Executive Officer, expanding his responsibilities as Chief Financial Officer to include overseeing daily operations. Mark M. Sieczkarek, the Company’s previous Chief Executive Officer, remains NovaBay’s Chairman and will focus on strategic growth opportunities that complement the Company’s continued organic growth.

  • Business Wire8 months ago

    NovaBay Pharmaceuticals to Present at H.C. Wainwright 20th Annual Global Investment Conference on September 6

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that management is scheduled to present a corporate overview at the H.C.

  • Business Wire8 months ago

    NovaBay Pharmaceuticals Reports Second Quarter 2018 Financial Results

    Conference call begins today at 4:30 p.m. Eastern time

  • Business Wire9 months ago

    NovaBay Pharmaceuticals to Hold Second Quarter 2018 Conference Call on August 7, 2018

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will report second quarter 2018 financial results after market close on Tuesday, August 7.

  • Business Wire9 months ago

    NovaBay Pharmaceuticals Expands Sales Organization to Re-energize Growth

    NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces it has completed the most recent planned expansion of its salesforce by hiring of 7 sales representatives. The Company now has a commercial salesforce of 45 representatives as the Company pursues profitable growth. “We are very encouraged by the high quality of our new hires, all of whom have significant experience in promoting prescription ophthalmic products,” said Mark M. Sieczkarek, NovaBay’s Chairman, President and CEO.

  • Business Wire11 months ago

    NovaBay Pharmaceuticals Reports First Quarter 2018 Financial Results

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, reports financial results for the three months ended March 31, 2018 and provides a business update.

  • Business Wire11 months ago

    NovaBay Pharmaceuticals to Hold First Quarter 2018 Conference Call on May 10, 2018

    NovaBay® Pharmaceuticals, Inc.  , a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report first quarter 2018 financial results after market close on Thursday, May 10.